# Melphalan, Prednisone, and CC-5013 (Revlimid) as Induction Therapy in Multiple Myeloma

> **NCT00396045** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Turin, Italy** · enrollment: 54 (—)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Revlimid (CC-5013)

## Key facts

- **NCT ID:** NCT00396045
- **Lead sponsor:** University of Turin, Italy
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** —
- **Final completion:** 2008-01
- **Target enrollment:** 54 (—)
- **Last updated:** 2006-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00396045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00396045, "Melphalan, Prednisone, and CC-5013 (Revlimid) as Induction Therapy in Multiple Myeloma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00396045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*